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Background: We describe a new method for biodistribution studies with IRDye800CW fluorescent antibody probes.
This method allows the quantification of the IRDye800CW fluorescent tracer in percentage of injected dose per
gram of tissue (% ID/g), and it is herein compared to the generally used reference method that makes use
of radioactivity.
Methods: Cetuximab was conjugated to both the near-infrared fluorophore IRDye800CW and/or the positron
emitter 89-zirconium, which was injected in nude mice bearing A431 human tumor xenografts. Positron emission
tomography (PET) and optical imaging were performed 24 h post-injection (p.i.). For the biodistribution study,
organs and tumors were collected 24 h p.i., and each of these was halved. One half was used for the determination
of probe uptake by radioactivity measurement. The other half was homogenized, and the content of the
fluorescent probe was determined by extrapolation from a calibration curve made with the injected probe.
Results: Tumors were clearly visualized with both modalities, and the calculated tumor-to-normal tissue ratios were
very similar for optical and PET imaging: 3.31 ± 1.09 and 3.15 ± 0.99, respectively. Although some variations were
observed in ex vivo analyses, tumor uptake was within the same range for IRDye800CW and gamma ray
quantification: 15.07 ± 3.66% ID/g and 13.92 ± 2.59% ID/g, respectively.
Conclusions: The novel method for quantification of the optical tracer IRDye800CW gives similar results as the
reference method of gamma ray quantification. This new method is considered very useful in the context of the
preclinical development of IRDye800CW fluorescent probes for optical molecular imaging, likely contributing to the
selection of lead compounds that are the most promising for clinical translation.
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Recent developments in the field of near-infrared fluor-
escence, with new fluorophores and new instrumenta-
tions, have contributed to the growing interest in optical
imaging [1-3] not only for noninvasive detection of
tumors, but also in the context of image-guided surgery
[4-6]. Thus far, clinical studies have been conducted with
indocyanine green (ICG), used as ‘blood pool’ contrast* Correspondence: p.vanbergen@uu.nl
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in any medium, provided the original work is pagent, enabling the visualization of highly vascularized
regions such as tumors or the detection of sentinel
lymph nodes. ICG was, until very recently, the only
near-infrared fluorophore approved for clinical use.
Importantly, the development of tumor-targeted
probes for optical imaging has encouraged many
researches in the last 10 years, leading to many recently
published preclinical studies. In this context, one of the
new near-infrared fluorophores widely employed is the
IRDye800CW (here abbreviated to IR). Not only can this
fluorophore be efficiently conjugated to antibodies,
smaller antibody fragments, or nanoparticles [7-11], butan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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a good manufacturing practice-compliant production
grade for clinical studies (since September 2010, LI-COR
communication, [12]). In fact, the first clinical trial in-
volving this fluorophore has just been initiated in The
Netherlands, where IR is conjugated to the monoclonal
antibody bevacizumab, an antibody that specifically
binds VEGF (Trial: NL37479.042.11).
One of the aspects that will make a probe in preclin-
ical development to be considered as a lead compound,
with potential for translation into the clinic, is its cap-
acity to accumulate specifically in the tumor, enabling
the acquisition of images with good contrast. In the pre-
clinical context, assessment of near-infrared probes' dis-
tribution in tumors and organs has been made either
with intact organs ex vivo or through imaging of tissue
sections, using the same systems as used for noninvasive
imaging of mice [9,11]. This practice only gives a relative
indication and qualitative assessment of the probes' tis-
sue distribution. Ideally, one would prefer to have a
method that allows for accurate quantification of the
near-infrared probe in percentage of injected dose per
gram of tissue (% ID/g), like it is commonly done with
radiolabeled probes. However, this accurate quantifica-
tion is actually not so simple due to the possibility of
quenching of the fluorescence when fluorophores are
present at a high concentration and also to the scatter-
ing of photons by tissue components.
Here, we describe a new method that circumvents the
above-mentioned limitation in quantification through
homogenization of the organs and dilution of the tissue
lysates in order to infer in the linear range of fluores-
cence. Furthermore, to demonstrate the validity of this
method, we have compared this method with the tradition-
ally used gamma ray quantification of radioactive-labeled
probes. For this, the monoclonal antibody cetuximab was
used as a model and was conjugated to both IR and 89-
zirconium (89Zr) forming a dual-labeled probe, i.e., 89Zr-
cetuximab-IR. Cetuximab is a chimeric (mouse/human)
monoclonal antibody that binds specifically to the epider-
mal growth factor receptor (EGFR), competing with lig-
and binding and promoting receptor internalization
and downregulation [13]. Currently used in the clinic for
cancer therapy, cetuximab has also been evaluated as a
probe for molecular imaging, both at preclinical [14,15]
and clinical levels (Prof. Guus van Dongen, personal
communication).
In this study, in order to compare the two biodistribu-
tion methods, cetuximab is employed as a dual-labeled
probe and intravenously injected in nude mice bearing
A431 human tumor xenografts. After the collection of
tumors and organs, each of these was divided into two
pieces so that both methods could be employed for
quantification of the probe in each organ.Methods
Production of (dual) labeled probes: 89Zr-cetuximab-IR
Two different probes were prepared: an imaging probe
and a biodistribution probe. The imaging probe is a mix-
ture of a radioactive-labeled probe and fluorescently la-
beled probe, i.e., 89Zr-cetuximab+ cetuximab-IR, while the
biodistribution probe is a dual-labeled probe, i.e., 89Zr-
cetuximab-IR. The monoclonal antibody (mAb) cetuxi-
mab (Erbitux; 5 mg/mL) was purchased from Merck
(Darmstadt, Germany) and, before any chemical modifica-
tion, cetuximab was buffer-exchanged on a PD10 column
(GE Healthcare Life Sciences, Eindhoven, The Netherlands)
to a solution of 0.9% NaCl. 89Zr (t1/2=78.4 h) was pur-
chased from IBA Molecular (Louvain-la-Neuve, Belgium)
as [89Zr]Zr-oxalate in 1.0 M oxalic acid (≥0.15 GBq/nmol)
(http://www.iba-molecular.com/).
Conjugation of chelator and radiolabeling
Cetuximab was modified using the chelator desferal (Df;
desferrioxamine B, Novartis Pharma BV, Arnhem, The
Netherlands) and subsequently labeled with 89Zr as
previously described by Cohen et al. [8]. The final con-
centration was 8.6 MBq/mg cetuximab for the biodistri-
bution probe and 182 MBq/mg cetuximab for the
imaging probe.
Conjugation of IRDye800CW
IRDye800CW-NHS ester (MW 1,166 Da, LI-COR Bios-
ciences (Lincoln, NE, USA); herein designated as IR)
was supplied by Westburg BV, Leusden, The Nether-
lands. For both the biodistribution probe and the im-
aging probe, the conjugation of IR was performed as
previously described [8]. In short, 89Zr-cetuximab or
cetuximab were brought to a pH of 8.5 by adding 0.1 M
Na2CO3. Subsequently, 20 μL of IR diluted in dimethyl
sulfoxide was added, and the total volume was adjusted
to 1 mL with 0.9% NaCl. The IR was added to the mAb
solution at a 2:1 molar ratio. The reaction mixture was
incubated for 2 h at 35°C in a thermomixer at 550 rpm.
The unreacted IR was removed by purification of the
conjugates on a PD10 column, using 0.9% NaCl as
eluent. The flow through and the first 1.5 mL were dis-
carded. The next 2 mL containing the conjugated mAb
was collected.
ITLC, HPLC, and SDS-PAGE analyses
The biodistribution probe and the imaging probe were
analyzed by instant thin-layer chromatography (ITLC)
for radiochemical purity, by high-performance liquid
chromatography (HPLC) for mAb integrity and purity,
and by sodium dodecyl phosphate polyacrylamide gel
electrophoresis (SDS-PAGE) for purity of the probes.
ITLC analysis was performed on silica gel-impregnated
glass fiber sheets (PI Medical Diagnostic Equipment BV,
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having a pH of 5.0 as the mobile phase. HPLC analysis
was performed on a JASCO Benelux BV HPLC (de
Meern, The Netherlands) with a diode array detector
system and an inline radiodetector (Raytest Isotopen-
messgeräte GmbH, Straubenhardt, Germany) using a
Superdex 200 10/300 GL size exclusion column (GE
Healthcare Life Sciences). The eluent consisted of
0.05 M sodium phosphate, 0.15 M sodium chloride, plus
0.05% sodium azide (pH 6.8), and the flow was set at a
rate of 0.5 mL/min. HPLC measurements were per-
formed at A= 280 nm to measure cetuximab absorption,
at A= 430 nm to measure the absorption of N-sucDf-Fe
(III), and at A= 780 nm to measure the absorption of IR.
The chelate-to-cetuximab and IR-to-cetuximab molar
ratios were determined by HPLC, using the areas under
the curve at A280, A430, and/or A780. Gel electrophor-
esis was performed as previously described [7,8]. In
short, SDS-PAGE of 89Zr-cetuximab-IR was performed
on a Phastgel system (GE Healthcare Life Sciences)
using 7.5% polyacrylamide gels at nonreducing
conditions, followed by phosphor imaging analysis. In
parallel, cetuximab and 89Zr-cetuximab-IR were size-
separated on a 15% polyacrylamide gel under reducing
conditions. These proteins were then stained with the
Coomassie Brilliant Blue solution (SERVA Electrophor-
esis GmbH, Heidelberg, Germany), and an Odyssey
scanner (LI-COR Biosciences) was used for detection,
employing the 800 nm detector for visualization of IR
and the 700 nm detector for visualization of the Coo-
massie stain.In vivo studies
Female athymic nude mice weighing 20 to 25 g and
being 7 to 8 weeks of age (Harlan Nederland, Horst, The
Netherlands) were housed in sterile cages under stand-
ard conditions (24°C, 60% relative humidity, 12-h light/
dark cycles) and provided with water and food ad libi-
tum. These studies were performed according to na-
tional regulations and approved by the local animal
experiments ethical committee. Subcutaneous tumors
were induced by inoculating two million cells of the
A431 human epidermoid carcinoma cell line at the right
and left hind legs. Approximately 1 week after tumor cell
inoculation, the tumor sizes were 100 to 200 mm3, and
the mice were randomly assigned to two different
groups: (a) imaging group, consisting of four mice that
were injected with the imaging probe, and (b) biodistri-
bution study group, consisting of six mice that were
injected with the biodistribution probe. All animal
experiments were done according to the NIH Principles
of Laboratory Animal Care and the Dutch national law
(Wet op de dierproeven, Stb 1985, 336).Optical imaging
During optical imaging, the mice were anesthetized with
2% isofluorane. Images were collected before and right
after injection of the imaging probe and at 24 h post-
injection (p.i.). Each image acquisition took less than
1 min, and images were obtained with two mice at a
time, using the IVIS Lumina system with ICG filter sets
(Caliper Life Science, Hopkinton, MA, USA). Data were
analyzed with the living image software from Xenogen
version 3.2 (Caliper LS).
PET imaging
Positron emission tomography (PET) imaging was per-
formed on a HRRT PET scanner (Siemens/CTI, Munich,
Germany [16]), a dedicated human brain scanner. The
mice were anesthetized by inhalation of 2% isofluorane,
and scanning time was 1 h. Transmission scans for at-
tenuation and scatter correction were routinely obtained
with each emission scan. Three-dimensional (3D) emis-
sion scans were acquired in list mode in 60 min. A
single-frame static image was reconstructed using ordin-
ary Poisson ordered subset expectation maximization.
For visualization of the images, the freely available Ami-
de's A Medical Imaging Data Examiner program was
used [17].
Biodistribution study
The mice were anesthetized, bled, euthanized, and dis-
sected 24 h after injection of the dual-labeled 89Zr-
cetuximab-IR, i.e., the biodistribution probe. Blood,
tumors, and several organs were halved; each piece was
weighed, and half was snap frozen for quantification of
the IR, while the other half was immediately prepared
for gamma quantification. No fixation of tissues was ap-
plied in any of these procedures.
Quantification of IR fluorescence
For IR fluorescence quantification, half of each organ
and tumor was disrupted with a TissueLyser II system
(Qiagen, Venlo, The Netherlands) using pre-cooled
Eppendorf holders, 5-mm stainless steel beads, and RIPA
buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 0.1% SDS) supplemented with
a complete EDTA-free mini tablet protease inhibitor
cocktail (Roche Applied Science, Penzberg, Germany).
Then, homogenates were diluted in series (1:2 dilution
steps) in 96-well plates, with the same buffer used for
homogenization of the organs, which is done to deter-
mine the range where fluorescence intensity varies in a
linear manner with the concentration. In parallel, the di-
lution series of the probe were also made using RIPA
buffer for the same purpose. The intensity of the IR
fluorescence of the samples and standard probe was
detected at 800 nm with the Odyssey scanner.
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the homogenates was extrapolated from the calibration
curves made with the standard probe, using the software
Prism 5 (GraphPad Software Inc., La Jolla, California,
USA). These concentration values were used to calculate
the percentage of injected dose per gram of tissue
(% ID/g), based on the volume of the homogenate and
the weight of the tumors and organs.
Quantification of gamma rays
For gamma ray quantification and the evaluation of the
biodistribution of 89Zr-cetuximab-IR, the other half of
each organ and tumor was placed in 8.5 mL tubes
(Sarstedt, Nümbrecht, Germany) with water, and the
amount of radioactivity was measured in a γ-well
counter (Wallac LKB-CompuGamma 1282; Pharmacia,
Uppsala, Sweden). Radioactivity uptake was measured as
% ID/g.
Statistics
Biodistribution data are presented as mean± SEM. The
agreement between the results obtained with the two dif-
ferent quantification methods was evaluated by the
Bland-Altman analysis including a linear regression ap-
proach [18,19]. For this, the average % ID/g of the 89Zr
and IR quantifications for each sample is plotted - on a
logarithmic scale in view of the observed range in %
ID/g - against the difference in % ID/g of both measure-
ments for each sample. To assess whether one of the two
quantification methods consistently exceeds the other,
the mean paired difference in % ID/g was calculated over
all samples. Linear regression was then used to assess
whether (1) the magnitude of this mean difference and
(2) the variation between the two quantification mea-
surements were related to the average % ID/g [19]. For
the magnitude, the differences in % ID/g were regressed
on the log-transformed average % ID/g values. As no
statistical evidence was found about the magnitude of the
between-method differences being related to the average
% ID/g, the line of best agreement was simply defined as
the overall mean paired difference in % ID/g over all
samples. For the variation, the absolute residuals around
the line of best agreement (as derived from the magni-
tude) were then regressed on the log-transformed aver-
age % ID/g values. Statistical evidence was found on the
variation between the two quantification measurements
which was related to the average % ID/g, with a
good log-linear fit. Using the results from these linear re-
gression analyses, the 95% limits of agreements between
the two methods were then calculated [19]. The line of
best agreement and the 95% limits of agreement are
shown in the Bland-Altman plot. Statistical analyses were
performed with the software Prism 5 (GraphPad
Software Inc., La Jolla, California, USA) and SPSSStatistics 17.0 (SPSS inc., Chicago, Illinois, USA), with a
two-sided cutoff for a statistical significance of 5%.Results
Production and analysis of 89Zr-cetuximab-IR
To employ the new method for quantification of fluores-
cent probes in tissues and, at the same time, to enable
the comparison with the reference method of gamma
ray quantification, a dual-labeled probe was produced.
The monoclonal antibody that binds to EGFR, i.e.,
cetuximab, was selected as a model system, and it was
conjugated to IR and/or radiolabeled with 89Zr. As
shown previously [8], this dual-labeling protocol is pos-
sible in a manner that does not affect the binding prop-
erties of cetuximab to EGFR nor the biodistribution of
the probe. Two probes were produced in this study: the
first probe was particularly prepared for the biodistribu-
tion study, consisting of cetuximab which was dually
conjugated to the radioactive and fluorescent label (i.e.,
dual-labeled biodistribution probe: 89Zr-cetuximab-IR);
and the second probe was dedicated for imaging and
consisted of a mixture of radioactive-labeled cetuximab
and fluorescently labeled cetuximab (i.e., imaging probe:
89Zr-cetuximab + cetuximab-IR). The differences are in
the radioactive dose, as PET imaging requires a higher
dose than the biodistribution studies.
Analysis of the biodistribution probe revealed that, on
average, the 0.5 group of the chelator Df was coupled to
cetuximab and the radiolabeling with 89Zr resulted in an
overall labeling yield of 70%. ITLC and HPLC showed
that the radiochemical purity of the product always
exceeded 95% after purification on PD10. The conjuga-
tion efficiency of IR to 89Zr-cetuximab was approxi-
mately 50%, resulting in 0.9 groups of IR per molecule
of 89Zr-cetuximab-IR as assessed by HPLC analysis.
After purification on PD10, the dual-labeled cetuximab
was found to be more than 99% pure for 89Zr as well as
for IR. For the imaging probe, the conjugation efficiency
of IR to cetuximab was approximately 70%, resulting in
1.4 groups of IR per molecule cetuximab. The purity of
the probes produced as well as the successful conjuga-
tion of 89Zr and IR was also confirmed by gel electro-
phoresis, highlighting the reproducibility of the
protocols employed.
Previous experiments have shown that the immunor-
eactivity of 89Zr-cetuximab-IR is 99% at infinite antigen
access studies [8]. Similarly, 89Zr-cetuximab-IR was
found to be stable when stored in 0.9% NaCl at 4°C for
at least 4 days, without any loss of integrity and immu-
noreactivity as assessed by HPLC or binding assays.
Moreover, only a minimal percentage of IR was found
to be released from the antibody when stored in hu-
man serum, i.e., approximately 1.4% [8]. Overall, the
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requirements needed for the following studies.
Optical and PET imaging
To observe the distribution of the EGFR-targeted probe
with the two imaging modalities, the nude mice bearing
A431 human tumor xenografts at the hind legs were
injected with the imaging probe. A group of four mice
was injected with 170 μL containing 38.3 μg of 89Zr-
cetuximab mixed with 62.72 μg of cetuximab-IR. At
24 h after injection of the probe, these mice were imaged
with an optical imager and a PET scanner. Both imaging
modalities allowed a very clear delineation of the tumors
(Figure 1). The abdominal area is also well visible, corre-
sponding mainly to the liver. From the images collected
and the registry of the individual weight of tumors at the
end of the experiment, a direct correlation is observed
between tumor weight and signal intensity which accu-
mulated at the tumors. Based on these images, tumor-
to-normal tissue (T/N) ratios were calculated by drawing
regions of interest around the tumors and in normal tis-
sues (namely at the head of the mice), for background
reference. The T/N ratios obtained were 3.31 ± 1.09 for
the optical images and 3.15 ± 0.99 for the PET images.a
b
Figure 1 Mice imaged with optical and PET modalities. Nude mice bea
24 h post-injection of the imaging probe, i.e., 89Zr-cetuximab+ cetuximab-I
ICG filter sets. (b) PET images representative of the entire scan (1 h), corona
determined at the end of the experiment, from left (L) to right (R), are as fo
mouse 3: L 0.529 g, R 0.2163 g; mouse 4: L 0.5474 g, R 0.2972 g.Overall, a similar probe distribution was observed in
the different images obtained with the two imaging
modalities.
Biodistribution assessed by IR fluorescence as well as
gamma ray quantifications
In order to apply both methods for assessment of the
biodistribution, i.e., the quantification of IR fluorescence
and the reference method of gamma ray quantification,
the following setup was employed: a group of six mice
was injected with 120 μL containing 106 μg of 89Zr-
cetuximab-IR, i.e., the biodistribution probe. Twenty
four hours later, each mouse was anesthetized, bled,
euthanized, and dissected, and each organ collected was
halved and weighed. One half of each organ was pro-
cessed for IR fluorescence quantification, and the other
half was processed for gamma ray quantification.
Quantification of gamma rays was performed using
established methods as described in the ‘Methods’ sec-
tion. The procedure for quantification of IR fluorescence
is depicted in Figure 2. In brief, the tumors and organs
were first homogenized and then diluted several times in
96-well plates. These plates were imaged with an Odys-
sey scanner to measure the IR fluorescence intensities,max
min
ring A431 human tumor xenografts at the hind legs were imaged
R. (a) Optical images taken with IVIS Lumina at 1-s exposure time and
l view. Tumors are indicated with arrows. Individual tumor weights
llows: mouse 1: L 0.2544 g, R 0.4353 g; mouse 2: L 0.4176 g, R 0.243 g;
1. Collect organ / cut / weight / snap freeze / store -80oC
2. Homogenize organ in RIPA buffer with metal bead (Tissuelyser)
3. Dilute organ lysate in 1:2 steps in 96-wells plate
4. Make calibration curve with 1% of injected dose diluted in 96-WP
5. Measure fluorescence intensities on Odyssey scanner
6. Extrapolate unknown concentrations from calibration curve
7. Calculate % injected dose / gram
1   2   3   4   5   6   7  8   9
1. Calibration curve
2. Tumor left
3. Tumor right
4. Liver
5. Kidney
6. Blood
7. Bladder
8. Skin
9. Muscle
a
b
Figure 2 New method for quantification of IR fluorescence in
tissues. (a) Overview of the method step-by-step. (b) Example of an
image obtained with the Odyssey scanner while measuring IR
fluorescence (shown in green) intensities from the calibration curve
and lysates of organs, all diluted in 1:2 steps in a 96-well plate (from
top to bottom). Saturation of the fluorescence is shown in white.
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diluted in order to make a calibration curve of concen-
tration versus fluorescence intensity (Figure 2). Espe-
cially in organs with the highest accumulation of the
fluorescent probe, saturation of the fluorescent signal
can occur, which will, without the dilution approach, re-
sult in an underestimation of the signal in the particular
organ (Figure 2b). From the obtained curve, the un-
known values of fluorescence of the diluted samples
were extrapolated, taking only the values of the dilutions
where linear range of fluorescence intensity was
detected. These concentration values, together with the
initial weight of the tumor or organ and the volume of
lysates, were then used to calculate the % ID/g values.
Both quantification methods led to comparable results
in % ID/g and, thus, comparable biodistributions
(Figure 3). In fact, for organs such as the tumor, liver,
lung, and skin, no significant differences in uptake were
obtained. Nevertheless, some differences obtained were
statistically significant, namely, the quantification of
probe in the blood, sternum, heart, spleen, kidney, and
muscle. These differences might be related to the catab-
olism of the probe and/or the different retentions of the
individual tracers, i.e., 89Zr and IR.
To compare the two sets of data, i.e., data obtained
from IR fluorescence quantification and from gamma
ray quantification, the Bland-Altman method of analysis
was employed. Most importantly, the values obtained
through gamma ray quantification are, on average, 0.63%
ID/g of tissue higher than those of IR fluorescence quan-
tification. This small average difference does not dependon the level of % ID/g itself (i.e., the average difference
between the two methods does not show a statistically
significant increase or decrease with increasing levels of
% ID/g, as assessed by linear regression analysis), and
could thus be solved by simple calibration. Furthermore,
the Bland-Altman plot shows that the absolute differ-
ence in the values obtained with the two methods for
matching samples (as each organ was split in two) is
very small for samples with a small average % ID/g of
tissue and that the variations between the two measure-
ments increase log linearly with higher average values
(as shown by the 95% limits of agreement indicated by
the dashed lines in Figure 4).
Discussion
During the last decade, many preclinical studies have
been evaluating new near-infrared fluorescent probes for
targeted molecular imaging, and the trend is to slowly
move towards the translation into clinical practice. How-
ever, before this can be done successfully, a thorough
and precise evaluation of the probe (or probes) is neces-
sary at the preclinical level. In this context, the precise
quantification of probes in tissues is a matter of concern
in biodistribution studies. The approach most commonly
used for assessment of tissue distribution of a probe
consists of imaging of organs or sections of organs with
an optical imager, only allowing for a relative or qualita-
tive assessment. This makes comparison between differ-
ent studies and different probes rather difficult, since no
% ID/g value is possible to be obtained in this manner.
This fact is related to the nature of fluorophores: their
close proximity can result in quenching of the fluores-
cence, leading to an underestimation of the amount of
probe in tissues. Also, the scattering of photons by tissue
components can compromise the fluorescence detected,
and moreover, the linear range of fluorescence detection
is restricted.
Here, we describe a new method for the quantification
of IRDye800CW fluorescent probes in tissues. This
method circumvents the issues mentioned above by di-
luting the lysate of the homogenized organs in order to
infer in the linear range of fluorescence (Figure 2). To
validate our new method, we have compared it with the
most commonly used method for biodistribution studies,
i.e., gamma ray quantification of radiolabeled probes. To
do so, and here as a research tool, a dual-labeled probe
was prepared, minimizing the possibility that the tissue
distribution of the probe would be affected by the differ-
ent labels. The monoclonal antibody cetuximab was
selected for this study as it was previously shown that
certain conditions of dual labeling do not affect its bio-
distribution [8]. This could not be the case for smaller
molecules or smaller antibody fragments due to the
reduced size. Hence, for the biodistribution study,
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Figure 3 Biodistribution of 89Zr-cetuximab-IR in tissues assessed by IR fluorescence and gamma ray quantifications. Tumors and organs
were collected 24 h p.i. of the biodistribution probe. Each organ was halved: one half was processed for IR fluorescence quantification and the
other half for gamma ray quantification. Six mice with two tumors each were employed; graph bars show mean values ± SEM. Statistical
significance is as follows: double asterisks for p< 0.01 and triple asterisks for p< 0.001.
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phore (IR) and to the positron emitter 89-zirconium
(89Zr), forming the dual-labeled 89Zr-cetuximab-IR, i.e.,
the biodistribution probe. To further minimize possible
variations, each organ and tumor that was collected for
the biodistribution study was halved so that one half
could be processed for IR fluorescence quantification
and the other half for gamma ray quantification. Never-
theless, one has to bear in mind the possibility of hetero-
geneous uptake in each tumor and organ, which could
lead to differences in uptake levels between the fluores-
cence and the radioactivity method.
Importantly, the results obtained with the two differ-
ent methods are very similar for tumors and organs such
as the liver, lung, stomach, skin, and intestines (Figure 3).
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Figure 4 Bland-Altman plot of IR quantification and gamma ray quan
best agreement (average difference 89Zr-IRDye, 0.63% ID/g of tissue); dasheheart, spleen, sternum, and muscle, showing higher
values by gamma ray quantification, and the kidney
which gave a higher value with IR fluorescence quantifi-
cation. As control studies have shown the stability of the
probe in serum, and as it is known that both 89Zr and IR
residualize after receptor-mediated internalization of
cetuximab ([20] and Dr. Mike Olive, personal communi-
cation), these variations are most likely related to what
happens to the probe after liver catabolism. In fact, deg-
radation of 89Zr-cetuximab-IR into small peptides is to
be expected, and the fate of these fragments after excre-
tion into the bile may vary, for instance, some of these
might be more effectively reabsorbed into the blood-
stream at the intestines and subsequently distribute dif-
ferently throughout the tissues. Even though this is
unclear, the trend suggested by the results presented%ID/g
tumor
blood
skin
sternum
heart
lung
liver
spleen
kidney
bladder
muscle
colon
ileum
stomach
10010
tification for probe content in tissues. Solid line denotes the line of
d lines denote 95% limits of agreement.
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http://www.ejnmmires.com/content/2/1/50here is that IR fragments are more efficiently eliminated
by kidney filtration, and 89Zr-fragments accumulate in
bone tissues like sternum, which is in agreement with
other studies [12,20-22].
It is worth realizing that true values of % ID/g are un-
known and that two groups of values have been
obtained, corresponding to the quantification of IR
fluorescence and gamma rays in the tissues. The aim of
this study was to determine whether comparable infor-
mation could be obtained with both quantification
methods. In this context, Bland-Altman plots are used
to compare the two sets of data and to determine how
much each data set differs from the mean value of the
two sets of data. Our results show a good average agree-
ment between the data sets. Although the 89Zr measure-
ments are, on average, slightly higher, this small average
difference does not depend on the level of % ID/g itself
and may thus be easily solved by a calibration factor.
The disagreement between the two methods increases
with higher values of % ID/g, e.g., in the spleen, tumor,
and liver (Figure 4). This observation could simply be
explained by a larger intra-organ variation in the case of
the spleen, liver, and the tumor. It also shows that for
between-group comparisons (e.g., a comparison between
the uptake of two probes), more subjects will probably
be needed to be able to detect a certain absolute average
difference between those groups, when the uptake is, on
average, high compared to low.
Overall, the results obtained through IR fluorescence
quantification are considered to be representative of the
results obtained with the reference method employed for
radiolabeled probes. This was also suggested initially by
the images obtained with the optical imager and the
PET scanner (Figure 1). In that part of the study, a
slightly different probe was employed (i.e., 89Zr-cetuxi-
mab + cetuximab-IR, the imaging probe), but in fact, no
differences were to be expected concerning the biodistri-
bution of these probes, as it has been previously investi-
gated that the conditions here employed for coupling of
IR or 89Zr are inert to cetuximab [8].
The optical images presented (Figure 1a) show a rela-
tively weaker signal at the tumors and livers compared to
the PET images (Figure 1b), but this is mostly related to
the modality employed. The optical imager employed
does not allow 3D collection of data, and fluorescence is
only detected at the surface, whereas the PET scanner
allowed for 3D collection of data. Recently, newer optical
imagers have been developed employing the so-called
fluorescence molecular tomography that is suggested to
be able to quantify proteins or probes deep in tissues
[23]. Nevertheless, background concentrations and
tumor-to-normal tissue ratios have been reported as lim-
iting factors [24], thus leaving room for the new method
here described to be used for accurate quantification ofIR fluorescent probes. In fact, this method will most
likely be applicable to other near-infrared fluorescent
probes, although residualization of the fluorophore
should be confirmed as well as the stability of the probe
in serum, being therefore advisable to be careful in gen-
eralizing this method to other fluorescent probes.
Even though the method for IR quantification is more
laborious than gamma ray quantification, this new
method enables accurate quantification of the probe in
% ID/g without the use of radionuclides. This fact is
indeed relevant when the probe under development is
meant for optical imaging and not for PET or SPECT
imaging. We have successfully applied this new method
for the quantification of IR fluorescent anti-EGFR nano-
bodies or VHHs in tissues [7]. In this study, we were
able to demonstrate that the small 15 kDa fluorescent
nanobodies accumulate more rapidly and to a greater
extent in A431 xenografts than the 150 kDa monoclonal
antibody cetuximab.
Conclusions
Here, we have presented a new method for ex vivo quan-
tification of IR fluorescence in tissues, which gives com-
parable results to the reference method used for
radiolabeled probes. Taking into account the current
trend, in optical imaging, of moving towards the transla-
tion of targeted fluorescent probes to clinical diagnostic
use, this new method is considered very valuable for pre-
clinical assessment of tissue distribution of IR fluores-
cent probes, with an accuracy that thus far was
inexistent. Thus, this new method can contribute to the
selection of lead compounds that are most promising for
clinical translation into probes for molecular imaging.
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